-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
R-10015
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2097938-51-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 2097938-51-5 |
| Description | R-10015 is an LIM domain kinase (LIMK) inhibitor that acts as a broad-spectrum antiviral drug for HIV infection. R-10015 blocks LIMK activity by binding to the ATP-binding pocket. |
Product Information
| Synonyms | R 10015; R10015 |
| IUPAC Name | methyl 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]-3H-benzimidazole-5-carboxylate |
| Molecular Weight | 410.86 |
| Molecular Formula | C20H19ClN6O2 |
| Canonical SMILES | COC(=O)C1=CC2=C(C=C1)N=C(N2)C3CCN(CC3)C4=NC=NC5=C4C(=CN5)Cl |
| InChI | InChI=1S/C20H19ClN6O2/c1-29-20(28)12-2-3-14-15(8-12)26-17(25-14)11-4-6-27(7-5-11)19-16-13(21)9-22-18(16)23-10-24-19/h2-3,8-11H,4-7H2,1H3,(H,25,26)(H,22,23,24) |
| InChIKey | MGRJCGXCUUCOQG-UHFFFAOYSA-N |
| Purity | 99.72% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Off-white to pink (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 604 |
| Exact Mass | 410.1258016 |
| In Vitro | R-10015 (100 μM; 0-4 hours) inhibits cofilin phosphorylation directly through blocking LIM kinase in CEM-SS T cells. R-10015 inhibits HIV-1 DNA synthesis, nuclear migration, and virion release. R-10015 inhibits multiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine encephalitis virus (VEEV), and herpes simplex virus 1 (HSV-1). |
| In Vivo | R-10015 (10 mg/kg; i.p.) displays none indication of toxicity. The result suggests the possibility of short-term use of LIMK inhibitors to block viral infections. |
| Target | LIM Kinase (LIMK); Reverse Transcriptase |
| XLogP3-AA | 3.4 |
